The Spanish guidelines suggest that switching to a STR in stable patients currently receiving 2 NRTIs and a PI and RTV offers added advantages in terms of treatment adherence and that the use of STRs is the most efficient strategy to prevent selective treatment non-adherence [3], that is the possibility for a patient to consume less pills than those effectively prescribed. The Italian guidelines recommend the use of

STRs and FDCs to improve durability of virologic suppression and to reduce the risk of developing AP26113 manufacturer resistance [4]. The European AIDS Clinical Society (EACS) guidelines recommend switching virologically suppressed patients for toxicity, to prevent long-term toxicity, and for simplification of a regimen. Therapeutic switches must always CH5424802 cost be performed within a context of known viral resistance and it must always be kept in mind that any drug combination has its LY3039478 clinical trial toxicological profile and that by switching it, it is possible to replace one set of toxicities with another. Nevertheless, it has been shown that the performance of patients who switched to an STR compared to patients remaining on a more complex regimen is superior, both in terms of virological response and persistence [5, 6]. Patient adherence is a problem in any chronic illness. A review of 76 studies across a wide range of therapeutic areas that measured adherence

using electronic monitoring has revealed that compliance rates in clinical trials are lower than previously assumed and that the number of prescribed doses per day is inversely related to compliance. According to electronic monitoring methods, the overall adherence rate was 71 ± 17%. Adherence Immune system to OD regimens was significantly higher than with 3-times-daily and 4-times-daily regimens, which reinforces the principle of simplicity [7]. Decreased cART adherence is associated either with patient-related factors such as substance

abuse, stress and depression, and with regimen-related factors. Regimen complexity includes the number of pills (pill burden), pill size, frequency and timing of doses, dietary and/or water requirements or restrictions, adverse events (AEs), medication storage requirements, number of prescriptions, number of copayments, refills, and medication bottles as well as the influence of these or other factors on the patient’s lifestyle. Pill count, dosing frequency, and AEs have the greatest impact on patients’ perceived ability to adhere to ARV medication regimens [8]. The exact rate of adherence necessary for cART treatment success is uncertain. Some studies indicate a minimum effective adherence rate of 80%, although a higher level (at least 95%) is considered ideal [9, 10]. More recent experience has shown that the relationship between treatment adherence and viral load suppression as well as resistance development can vary among drug classes [11–13]. Several studies have shown that patients prefer OD regimens and simpler schedules [14–18].